Skip to site menu Skip to page content

13 Keys to a Successful Monoclonal Antibody BLA Submission

By Modality Solutions

When a monoclonal antibody therapy advances through its development lifecycle, planning ahead and optimising the biopharmaceutical cold chain is key to advancing towards approval.

Monoclonal antibody treatments have specific requirements for shipping validation and require a more precise and thorough regulatory submission process—which starts with a biologics license application (BLA) filing.

In this guide, we’ll go over what you need to know to ensure your cold chain is ready for a successful filing.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Related Content